Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Biogen’s experimental Alzheimer’s drug diranersen reduced tau levels in early-stage patients and slowed cognitive decline in a Phase 2 trial. Meanwhil...
